Showing 3841-3850 of 6805 results for "".
- Pulse Biosciences Survey: Clearing Pigmented Lesions is No. 1 Priority for Manyhttps://practicaldermatology.com/news/pulse-biosciences-survey-clearing-pigmented-lesions-is-no-1-priority-for-many/2460786/A majority of patients with unwanted benign lesions are interested in a new procedure to clear these lesions, according to a new survey by Pulse Biosciences that was presented at the American Academy of Dermatology (AAD) Virtual Annual Meeting. A diverse sample of 405 aesthetic patients
- AAD Survey: One-Third of Americans Flunk Basic Quiz on Skin Cancer and Sun Exposurehttps://practicaldermatology.com/news/aad-survey-one-third-of-americans-flunk-basic-quiz-on-skin-cancer-and-sun-exposure/2460785/One-third of Americans lack a basic understanding of skin cancer and sun protection, according to a recent survey of 1,000 U.S. adults from the American Academy of Dermatology. Shockingly, more than half (53%) of adults are unaware that shade can protect them from the sun’s harmfu
- Data Show Amgen's Otezla Benefits Patients with Mild-to-Moderate Psoriasishttps://practicaldermatology.com/news/data-show-amgens-otezla-benefits-patients-with-mild-to-moderate-psoriasis/2460775/Amgen’s Otezla (apremilast) improved measures of disease severity in adults with mild-to-moderate plaque psoriasis regardless of their Body Surface Area (BSA) involvement, according to findings from the placebo-controlled, phase 3 ADVANCE trial, presented at the AAD VMX 2021
- San Francisco Dermatologist Bill Kwan Featured in Third Albumhttps://practicaldermatology.com/news/san-francisco-dermatologist-bill-kwan-featured-in-third-album/2460773/As a dermatologist, Bill Kwan, MD plies his craft as the provider of both medical and aesthetic care to patients in San Francisco. As a vocalist, he plies his craft sharing the art of music. Dr. Kwan has released "No Ordinary Love: The Music of Sade." The third album that features Dr. K
- Burt's Bees Nature-Based Ingredients Protect Against Evolving Skincare Challengeshttps://practicaldermatology.com/news/burts-bees-nature-based-ingredients-protect-against-evolving-skincare-challenges/2460772/Burt's Bees bakuchiol bests retinol when it comes to promoting expression of certain anti-aging genes, according to a poster presented at the 2021 American Academy of Dermatology Virtual Meeting Experience. And other new research supports the moisturization and skin barrier benefits
- Skin Bleaching for a Lighter Complexion Carries Serious Riskshttps://practicaldermatology.com/news/skin-bleaching-for-a-lighter-complexion-carries-serious-risks/2460769/Despite the potential dangers of skin bleaching products, the global market for skin lighteners last year was estimated at $8.6 billion and is projected to reach $12.3 billion by 2027. “The cultural beliefs that promote the practice of skin bleaching date back centuries
- Promising Phase 3 Data for Oral Deucravacitinib from Bristol Myers Squibb in Psoriasishttps://practicaldermatology.com/news/promising-phase-3-data-for-oral-deucravacitinib-from-bristol-myers-squibb-in-psoriasis/2460765/In two pivotal Phase 3 trials evaluating deucravacitinib 6mg once daily for the treatment of patients with moderate to severe plaque psoriasis, significantly more patients met both co-primary endpoints—Psoriasis Area and Severity Index (PASI) 75 response and a static Physician's Global
- UCB’s Bimekizumab Outplays the Competition in Two Phase 3 Psoriasis Trialshttps://practicaldermatology.com/news/ucbs-bimekizumab-outplays-the-competition-in-two-phase-3-psoriasis-trials/2460764/UCB’s Bimekizumab almost entirely cleared moderate to severe psoriasis in more than 60 percent of the patients who took part in two Phase 3 clinical trials. Given via injection under the skin, Bimekizumab is a monoclonal antibody and the first to block both Interleukin 17A and Int
- Phase 3 Data Show Tolerability, Efficacy for Brickell's Sofpironium Bromide in Hyperhidrosishttps://practicaldermatology.com/news/phase-3-data-show-tolerability-efficacy-for-brickells-sofpironium-bromide-in-hyperhidrosis/2460763/Data from the phase 3, open-label, long-term safety study of Brickell Biotech’s sofpironium bromide gel, 5% and 15%, provided clinically meaningful improvement in axillary hyperhidrosis severity as measured by the Hyperhidrosis Disease Severity Measure-
- Biosimilar News: Switching Study Shows Cyltezo and Humira Are Interchangeablehttps://practicaldermatology.com/news/biosimilar-news-switching-study-shows-cyltezo-and-humira-are-interchangeable/2460762/Switching between adalimumab biosimilar Cyltezo and its reference product results in similar pharmacokinetics, efficacy, safety and immunogenicity in people with moderate-to-severe chronic plaque psoriasis, according to new Phase 3 data presented at the American Academy of Dermatology 2021 virtua